Publicaciones en colaboración con investigadores/as de University of California Los Angeles (15)

2023

  1. Oligometastatic Hormone-Sensitive Prostate Cancer. Why Radiotherapy?

    Clinical Genitourinary Cancer, Vol. 21, Núm. 3, pp. e93-e103

  2. PSMA PET/CT imaging for biochemical recurrence of prostate cancer after radiotherapy: is it necessary to review the Phoenix criteria?

    Clinical and Translational Imaging, Vol. 11, Núm. 3, pp. 241-254

2020

  1. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer

    New England Journal of Medicine, Vol. 382, Núm. 7, pp. 610-621

2019

  1. Salivaomics in oral cancer

    Current Opinion in Otolaryngology and Head and Neck Surgery, Vol. 27, Núm. 2, pp. 91-97

2018

  1. Salivary exRNA biomarkers to detect gingivitis and monitor disease regression

    Journal of Clinical Periodontology, Vol. 45, Núm. 7, pp. 806-817

  2. The need to educate future dental professionals on E-cigarette effects

    European Journal of Dental Education, Vol. 22, Núm. 4, pp. e751-e758

2017

  1. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial

    The Lancet Oncology, Vol. 18, Núm. 7, pp. 904-916

  2. Emerging technologies for salivaomics in cancer detection

    Journal of Cellular and Molecular Medicine, Vol. 21, Núm. 4, pp. 640-647

  3. Saliva diagnostics – Current views and directions

    Experimental Biology and Medicine, Vol. 242, Núm. 5, pp. 459-472

  4. The Polyanalgesic Consensus Conference (PACC): Recommendations for Intrathecal Drug Delivery: Guidance for Improving Safety and Mitigating Risks

    Neuromodulation, Vol. 20, Núm. 2, pp. 155-176

2016

  1. Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): An open-label, randomised, phase 3 trial

    The Lancet Oncology, Vol. 17, Núm. 3, pp. 357-366

  2. HERMIONE: A randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer

    BMC Cancer, Vol. 16, Núm. 1

2015

  1. Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): A randomised, open-label, multicentre, phase 2 trial

    The Lancet Oncology, Vol. 16, Núm. 16, pp. 1700-1710

2014

  1. Intrarenal and extrarenal autonomic nervous system redefined

    Journal of Urology, Vol. 191, Núm. 4, pp. 1060-1065

  2. The appropriate use of neurostimulation of the spinal cord and peripheral nervous system for the treatment of chronic pain and ischemic diseases: The neuromodulation appropriateness consensus committee

    Neuromodulation, Vol. 17, Núm. 6, pp. 515-550